 |
|
|
| |
24-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study
|
| |
| |
13th IAS Conference on HIV Science; July 13–17, 2025; Kigali, Rwanda
Christoph Wyen,
|
| |
|
|
|
|
|
